Epineuron recently announced the official launch of an FDA clinical trial for PeriPulse™, breakthrough solution for bioelectronic nerve regeneration therapy. Building on robust research led by its scientific and clinical advisory board, the company has successfully obtained regulatory approval to conduct a multicentre clinical trial in traumatic acute nerve injury for this breakthrough therapy.
Epineuron is an alumnus of the BDSP™, CAAP®, HealthMINT™, H2BB™, and WiHI programs, and presented at the OBIO® Investment Summit.